27412534|t|In Vitro Assays for the Discovery of PCSK9 Autoprocessing Inhibitors
27412534|a|PCSK9 plays a significant role in regulating low-density lipoprotein (LDL) cholesterol levels and has become an important drug target for treating hypercholesterolemia. Although a member of the serine protease family, PCSK9 only catalyzes a single reaction, the autocleavage of its prodomain. The maturation of the proprotein is an essential prerequisite for the secretion of PCSK9 to the extracellular space where it binds the LDL receptor and targets it for degradation. We have found that a construct of proPCSK9 where the C-terminal domain has been truncated has sufficient stability to be expressed and purified from Escherichia coli for the in vitro study of autoprocessing. Using automated Western analysis, we demonstrate that autoprocessing exhibits the anticipated first-order kinetics. A high-throughput time-resolved fluorescence resonance energy transfer assay for autocleavage has been developed using a PCSK9 monoclonal antibody that is sensitive to the conformational changes that occur upon maturation of the proprotein. Kinetic theory has been developed that describes the behavior of both reversible and irreversible inhibitors of autocleavage. The analysis of an irreversible lactone inhibitor validates the expected relationship between potency and the reaction end point. An orthogonal liquid chromatography-mass spectrometry assay has also been implemented for the confirmation of hits from the antibody-based assays.
27412534	0	15	In Vitro Assays	T062	C1515653
27412534	24	33	Discovery	T052	C1880355
27412534	37	68	PCSK9 Autoprocessing Inhibitors	T121	C4051515
27412534	69	74	PCSK9	T116,T126	C4255394
27412534	103	113	regulating	T038	C1327622
27412534	114	162	low-density lipoprotein (LDL) cholesterol levels	T059	C0202117
27412534	139	142	LDL	T109,T123	C0023823
27412534	191	202	drug target	T169	C1521840
27412534	207	215	treating	T169	C1522326
27412534	216	236	hypercholesterolemia	T047	C0020443
27412534	263	285	serine protease family	T116,T126	C2717971
27412534	287	292	PCSK9	T116,T126	C4255394
27412534	298	307	catalyzes	T067	C1254366
27412534	310	325	single reaction	T169	C0443286
27412534	331	343	autocleavage	T067	C1254366
27412534	351	360	prodomain	T087	C1514562
27412534	366	376	maturation	T040	C0678723
27412534	384	394	proprotein	T116	C1709708
27412534	411	423	prerequisite	T078	C0679209
27412534	432	441	secretion	T038	C0036536
27412534	445	450	PCSK9	T116,T126	C4255394
27412534	458	477	extracellular space	T030	C0015352
27412534	487	492	binds	T052	C1145667
27412534	497	509	LDL receptor	T116,T192	C0034821
27412534	514	521	targets	T169	C1521840
27412534	529	540	degradation	T169	C0243125
27412534	563	584	construct of proPCSK9	T116	C1709708
27412534	595	612	C-terminal domain	T087	C1514562
27412534	622	631	truncated	T080	C0849355
27412534	647	656	stability	T080	C0205360
27412534	663	672	expressed	T045	C0017262
27412534	677	685	purified	T169	C1998793
27412534	691	707	Escherichia coli	T007	C0014834
27412534	716	730	in vitro study	T062	C0681828
27412534	734	748	autoprocessing	T067	C1254366
27412534	756	782	automated Western analysis	T059,T063	C0005863
27412534	804	818	autoprocessing	T067	C1254366
27412534	832	843	anticipated	T033	C3840775
27412534	844	864	first-order kinetics	UnknownType	C0878685
27412534	868	883	high-throughput	T059	C2718002
27412534	884	942	time-resolved fluorescence resonance energy transfer assay	T059	C0597717
27412534	947	959	autocleavage	T067	C1254366
27412534	987	1012	PCSK9 monoclonal antibody	T116,T129	C0003250
27412534	1021	1030	sensitive	T169	C0332324
27412534	1038	1060	conformational changes	T044	C0301641
27412534	1077	1087	maturation	T040	C0678723
27412534	1095	1105	proprotein	T116	C1709708
27412534	1107	1121	Kinetic theory	T070	C1254365
27412534	1160	1168	behavior	T053	C0004927
27412534	1177	1187	reversible	T121	C1254351
27412534	1192	1215	irreversible inhibitors	T121	C1254351
27412534	1219	1231	autocleavage	T067	C1254366
27412534	1237	1245	analysis	T062	C0936012
27412534	1252	1282	irreversible lactone inhibitor	T121	C1254351
27412534	1306	1318	relationship	T080	C0439849
27412534	1327	1334	potency	T080	C3245505
27412534	1343	1351	reaction	T169	C0443286
27412534	1352	1361	end point	T080	C2349179
27412534	1366	1422	orthogonal liquid chromatography-mass spectrometry assay	T059	C0872318
27412534	1437	1448	implemented	T033	C0243095
27412534	1487	1508	antibody-based assays	T059	C0005507